If you or a loved one has taken Tysabri and are concerned about progressive multifocal leukoencephalopathy (PML), understanding the timeline of exposure and reported cases is crucial. The medical and scientific community has long tracked adverse drug events to improve patient safety, and this page reviews documented reports and monitoring considerations specific to Illinois.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn’s disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. This narrative reviews the medical evidence linking Tysabri to PML, the clinical presentation and diagnosis of PML, and risk-related considerations for affected patients, including legal factors such as the statute of limitations in Illinois. Progressive Multifocal Leukoencephalopathy: Clinical Presentation and Diagnosis PML is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation varies but commonly includes progressive neurological deficits such as weakness, gait disturbance, balance disorder, cognitive impairment, memory loss, and visual changes. In Tysabri-treated patients, symptoms may be subtle initially, making early diagnosis challenging. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction. Brain biopsy may be required in uncertain cases. The FDA Adverse Event Reporting System (FAERS) data for Tysabri lists frequent reports of fatigue, multiple sclerosis relapse, headache, gait disturbance, memory impairment, asthenia, balance disorder, hypoesthesia, muscular weakness, cognitive disorder, and mobility decreased (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these symptoms overlap with multiple sclerosis, they can also signal PML onset, underscoring the need for vigilant monitoring.
Tysabri is a monoclonal antibody that binds to alpha-4 integrin, blocking lymphocyte adhesion and migration into the central nervous system. This mechanism reduces inflammatory demyelination in multiple sclerosis but also impairs immune surveillance against JCV. The FDA-approved labeling includes a boxed warning stating that Tysabri increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three established risk factors for PML in Tysabri-treated patients are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label advises healthcare professionals to consider these factors in the context of expected benefit when initiating and continuing treatment. Tysabri is available only through the restricted TOUCH Prescribing Program to manage PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic link between Tysabri and PML involves impaired immune surveillance. By blocking lymphocyte trafficking into the brain, Tysabri reduces the ability of the immune system to control JCV replication. JCV is a ubiquitous virus that remains latent in healthy individuals. In the setting of reduced central nervous system immune surveillance, JCV can reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the clinical syndrome of PML. The risk increases with cumulative exposure to Tysabri, as longer treatment duration allows more time for JCV reactivation and progression to clinical disease.
The FDA-approved labeling for Tysabri contains a boxed warning that clearly states the increased risk of PML and identifies known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, questions may arise about whether prescribers adequately communicated the risk to patients, especially regarding the significance of anti-JCV antibody status and the cumulative risk over time. For patients who developed PML, the adequacy of informed consent and risk communication may be relevant in legal contexts. For patients in Illinois who developed PML after Tysabri treatment, legal considerations include the statute of limitations for filing a claim. In Illinois, personal injury claims generally must be filed within two years from the date the injury was discovered or reasonably should have been discovered. For PML, the timeline between exposure to Tysabri and documented harm can be variable, often spanning months to years. The latency period complicates the determination of when the injury was discoverable. Patients or their families should consult with an attorney experienced in pharmaceutical litigation to assess the specific facts of their case, including the date of PML diagnosis, the duration of Tysabri treatment, and any prior immunosuppressant use. The presence of anti-JCV antibodies and treatment duration beyond two years are key risk factors that may influence both medical and legal assessments. The risk of PML increases with longer Tysabri treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, PML can occur earlier, particularly in patients with additional risk factors such as prior immunosuppressant use or positive anti-JCV antibody status. The onset of symptoms may be insidious, and diagnosis may be delayed. Once PML is diagnosed, the prognosis is poor, with most patients experiencing severe disability or death. The timeline from initial Tysabri exposure to PML diagnosis is critical for both medical management and legal purposes, as it affects the statute of limitations and the ability to establish causation. In summary, Tysabri is associated with a well-documented risk of PML, with specific risk factors identified in the FDA-approved labeling. Patients who develop PML face severe outcomes, and legal considerations in Illinois include the statute of limitations, which typically requires filing within two years of discovering the injury. Affected individuals should seek both medical and legal guidance promptly.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Illinois, personal injury claims generally must be filed within two years from the date the injury was discovered or reasonably should have been discovered. For PML, the latency period can complicate this timeline, so it is crucial to consult an attorney promptly after diagnosis.
The three established risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are outlined in the FDA-approved labeling (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.